Pantoprazole 40mg + Domperidone 10mg
Pantoprazole 40mg (irreversible H⁺/K⁺-ATPase inhibition, lowest CYP2C19 drug interaction liability) + Domperidone 10mg IR (peripheral D2 antagonist prokinetic/anti-emetic). The 10×15 Alu economy format provides 150 combination tablets for chronic GORD-dyspepsia management. Immediate-release domperidone 10mg provides meal-time targeted prokinetic activity.
GORD with functional dyspepsia, post-prandial bloating with reflux, nausea with acid-related conditions, and chronic GORD maintenance with motility component. The economy 150-tablet pack serves the same chronic maintenance market as PANSWING™ 40 but adds domperidone for patients with concurrent motility symptoms.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PANSWING™ D's economy format mirrors PANSWING™ 40 for the combination PPI-prokinetic market — providing the same chronic prescribing convenience (75-day supply per box) for patients requiring both acid suppression and prokinetic support.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.